Review
doi: 10.1016/s0304-3835(00)00648-0.
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications
Affiliations
- PMID: 11164186
- DOI: 10.1016/s0304-3835(00)00648-0
Item in Clipboard
Review
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications
Cancer Lett.
2001 Jan.
Abstract
Alterations of the epidermal growth factor receptor (EGFR) occur frequently in malignant gliomas through gene amplification or rearrangement, especially in a large fraction of de novo type glioblastomas. The most common of these mutant EGFRs (variously named de2-7 EGFR, deltaEGFR or EGFRvIII) lacks a portion of the extracellular ligand-binding domain. Here, we review the evidence that shows that expression of deltaEGFR bestows in vivo growth advantages to human glioma cells through its constitutively active tyrosine kinase activity. Thus, deltaEGFR may provide a novel therapeutic target for the most aggressive type of glioblastoma.
Similar articles
-
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9. doi: 10.1073/pnas.95.10.5724. Proc Natl Acad Sci U S A. 1998. PMID: 9576951 Free PMC article.
-
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.J Neurosurg. 2001 Sep;95(3):472-9. doi: 10.3171/jns.2001.95.3.0472. J Neurosurg. 2001. PMID: 11565870
-
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.J Biol Chem. 1997 Jan 31;272(5):2927-35. doi: 10.1074/jbc.272.5.2927. J Biol Chem. 1997. PMID: 9006938
-
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.Neoplasia. 2010 Sep;12(9):675-84. doi: 10.1593/neo.10688. Neoplasia. 2010. PMID: 20824044 Free PMC article. Review.
-
The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.Expert Opin Ther Targets. 2007 Apr;11(4):463-72. doi: 10.1517/14728222.11.4.463. Expert Opin Ther Targets. 2007. PMID: 17373877 Review.
Cited by
-
Genetic variations in EGF and EGFR and glioblastoma outcome.Neuro Oncol. 2010 Aug;12(8):815-21. doi: 10.1093/neuonc/noq018. Epub 2010 Mar 2. Neuro Oncol. 2010. PMID: 20197289 Free PMC article.
-
ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.Oncotarget. 2015 Aug 21;6(24):20388-95. doi: 10.18632/oncotarget.3981. Oncotarget. 2015. PMID: 25978031 Free PMC article.
-
iNOS: a potential therapeutic target for malignant glioma.Curr Mol Med. 2013 Sep;13(8):1241-9. doi: 10.2174/1566524011313080002. Curr Mol Med. 2013. PMID: 23590833 Free PMC article. Review.
-
Immunohistochemical markers for prognosis of ependymal neoplasms.J Neurooncol. 2002 Jul;58(3):255-70. doi: 10.1023/a:1016222202230. J Neurooncol. 2002. PMID: 12187959
-
EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration.J Cell Sci. 2020 Dec 24;133(24):jcs247189. doi: 10.1242/jcs.247189. J Cell Sci. 2020. PMID: 33243756 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
